Liquid Biopsies – Products

This digital PCR system for DNA and RNA features 6 advanced optical channels for flexible, multiplexed biomarker detection, with advances in sensitivity, precision and flexibility. The Digital LightCycler® System is a powerful digital PCR system that aims to help laboratories push the boundaries of clinical research forward

Personalis, Inc. has announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.

Personalis, Inc., National Cancer Center and Ono Pharmaceutical Co., Ltd. have announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.

Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.

Telesis Bio Inc. has announced the continued expansion of the BioXp® Select Kit product line, releasing two novel kits to enable DNA amplification and scale-up.

Certis Oncology Solutions has announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

Personalis, Inc., Cancer Research UK’s Cancer Research Horizons, University College London and the Francis Crick Institute have announced a collaboration to deploy a personalized liquid biopsy-based research assay, for the TRACERx study.

Download this app note to learn how you can select 20 individual CTCs in 10 minutes, this approach can be used for DNA, RNA or proteome analysis as well as how these target cells are selected and isolated in high purity from heterogenous backgrounds.

Personalis, Inc. has announced it will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.

Diagnostic tests are at the core of medicine. Liquid biopsies in particular are incredibly valuable, giving a more holistic disease profile and making it easier to measure a condition over time.